DOCSLIB.ORG

A Prospective Study of G-CSF Effects on Hemostasis in Allogeneic Blood Stem Cell Donors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Prospective Study of G-CSF Effects on Hemostasis in Allogeneic Blood Stem Cell Donors Bone Marrow Transplantation, (1999) 23, 991–996 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors R LeBlanc1, J Roy1, C Demers1,LVu2 and G Cantin1 1St Sacrement Hospital, Laval University, Quebec City; and 2St Sacrement Hospital, Quebec City, Quebec, Canada Summary: The last few years have witnessed an important increase in the use of peripheral blood stem cells (PBSC) for allogeneic Granulocyte colony-stimulating factor (G-CSF) is used in transplantation. Granulocyte colony-stimulating factor (G- healthy donors of peripheral blood stem cells (PBSC) for CSF) is currently the most widely used cytokine for stem allogeneic transplantation. However, some data have cell mobilization. Exposing a large number of otherwise recently suggested that G-CSF may induce a hypercoag- healthy individuals to G-CSF raises concerns about poten- ulable state, prompting us to study prospectively 22 tial adverse effects.1 Although usually well tolerated, G- PBSC donors before and after G-CSF 5 ␮g/kg twice CSF administration commonly induces side-effects such as daily. We sought evidence for changes in the following bone pain, headaches, fatigue and nausea. Anxiety, noncar- parameters: platelet count, von Willebrand factor anti- diac chest pain, myalgia, insomnia, fever, night sweats, skin gen (vWF:Ag) and activity (vWF activity), ␤-thrombo- rash, anorexia, dizziness, weight gain, local reactions at the globulin (␤-TG), platelet factor 4 (PF-4), platelet acti- injection site and vomiting have been infrequently reported. vation markers (GMP-140 and PAC-1), activated partial G-CSF has been extensively used for the treatment of neu- thromboplastin time (aPTT), prothrombin time (PT), tropenia following chemotherapy, but short- and long-term coagulant factor VIII (FVIII:C), thrombin–antithrombin side-effects of G-CSF in normal individuals are not well complex (TAT), prothrombin fragment 1+2(F1+2), defined. thrombomodulin (TM) and tissue plasminogen activator In a few small studies, G-CSF was found to induce plate- antigen (tPA:Ag) prior to G-CSF and immediately before let activation. Shimoda and others have shown that G-CSF leukapheresis. ADP-induced platelet aggregation studies receptors are present on the surface of platelets.2,3 These were also performed. G-CSF administration produced receptors appear to be functional in vitro2 and in vivo4,5 in only mild discomfort. We found a significant increase in healthy volunteers. However, the consequences on hemo- vWF:Ag (from 0.99 ؎ 0.32 U/ml to 1.83 ؎ 0.69 U/ml; P stasis of these findings are conflicting. Other investigators Ͻ 0.001), in vWF activity (from 1.04 ؎ 0.34 U/ml to have also observed an increase in platelet aggregation, in U/ml; P Ͻ 0.001) and in FVIII:C (from platelet activation, in von Willebrand factor and in 0.50 ؎ 1.78 U/ml to 1.73 ؎ 0.57 U/ml; P Ͻ 0.001) after thrombin–antithrombin complex after G-CSF, but these 0.37 ؎ 1.12 G-CSF. Of note, four donors with low baseline vWF had results could not be confirmed.2,4–10 a two- to three-fold increase after receiving G-CSF. G- To date, two cases of thrombosis occurring in normal CSF had no impact on the platelet count, ␤-TG, PF-4, donors have been reported.11 The first one was a healthy GMP-140 or PAC-1. The final% of platelet aggregation 54-year-old woman who developed a cerebrovascular acci- decreased from 73 ؎ 22% to 37 ؎ 26% after G-CSF (P dent 2 days after completing an uneventful stem cell Ͻ 0.001). We found a significant decrease in aPTT after donation. The second one was a 64-year-old man with a -G-CSF (29.9 ؎ 3.1 s to 28.3 ؎ 3.3 s; P = 0.004), but the history of coronary artery disease who experienced a myo PT was unaffected. In addition, we also observed a sig- cardial infarction shortly after PBSC collection. nificant increase in TAT, F1+2 and TM, but not in These clinical and biological observations raise concerns tPA:Ag. Our data suggest that G-CSF may possibly about the possibility that G-CSF might in fact induce a hy- induce a hypercoagulable state by increasing levels of percoagulable state in healthy donors and consequently, FVIII:C and thrombin generation. In contrast to this increase the risk of thrombosis. In order to better define the information, we found reduced platelet aggregation after effects of G-CSF on hemostasis, we undertook a prospec- G-CSF administration. The clinical implications of these tive study in healthy PBSC donors focusing on short-term findings remain unclear and larger studies are defi- adverse effects and on hemostatic changes immediately nitely required. after G-CSF administration. Keywords: granulocyte colony-stimulating factor; plate- let activation; thrombosis; healthy peripheral blood stem cell donors Materials and methods Study design Correspondence: Dr R LeBlanc, CHA, Pavillon Saint-Sacrement, 1050, chemin Sainte-Foy, Que´bec (Qc), Canada G1S 4L8 This is a cohort study, conducted at St Sacrement Hospital, Received 27 July 1998; accepted 22 December 1998 Laval University, Quebec City, Canada. It was approved Effect of G-CSF on hemostasis in allogeneic blood stem cell donors R LeBlanc et al 992 by the institutional review board and written consent was coagulant factor VIII (FVIII:C), von Willebrand factor anti- obtained from all healthy donors prior to participation. gen (vWF:Ag) and activity (vWF activity), thrombin– antithrombin complex (TAT), prothrombin fragment 1+2 + Patients (F1 2), thrombomodulin (TM) and tissue plasminogen acti- vator antigen (tPA:Ag) assays were performed on plasma Between July 1996 and April 1998, all consecutive healthy obtained from anticoagulated blood with citrate (Becton allogeneic PBSC donors were considered for enrollment in Dickinson, 0.105 mol/l) and centrifuged at 2500 g for 15 the study. All donors studied were used as their own con- min at 4°C. Plasma samples were analyzed immediately or trol. Donors were excluded if they had an abnormal platelet stored in aliquots at Ϫ80°C until tested. For assaying, count, bleeding time, activated partial thromboplastin time samples were thawed for 15 min in a 37°C water-bath. The (aPTT) or prothrombin time (PT) prior to G-CSF. Other Monovette blood collection system (Sarstedt, NC, USA) exclusion criteria were a history of unstable angina, myo- containing sodium citrate (0.105 mol/l) was used for plate- cardial infarction, ischemic or thrombotic stroke in the past let aggregation. Platelet-rich plasma was obtained by centri- 3 months, active neoplasia, active inflammatory disease, fugation at 250 g for 6 min at 27°C and was adjusted with pregnancy or a contra-indication to blood donation. platelet-poor plasma (2500 g for 15 min at 27°C) to a plate- let count of 200 × 109/l. Intervention Assays: Ivy bleeding time was performed with the Simp- All donors were evaluated initially by a physician and a late IIR device (Organon Teknika, Durham, NC, USA) with nurse with a complete medical history and physical examin- longitudinal incisions. Platelet counts were measured on a ation. At their first visit, they were instructed on how to Coulter STKS (Miami, FL, USA). Platelet activation mark- administer their medication and on the potential side- ers (GMP-140 and PAC-1) were measured by flow cytome- effects. Before the first dose of G-CSF, blood samples were try with argon laser generating laser light at 488 nm drawn for laboratory evaluation. All donors received G- (Coulter Epics XL-MCL) using 20 ␮l of anti-P-selectin (Pe, CSF (Neupogen, Amgen, Mississauga, Canada) at 5 ␮g/kg B-D) fluorescing at 575 nm and 20 ␮l anti-gpIIb-IIIa subcutaneously twice daily for nine consecutive doses. (FITC, B-D) fluorescing at 525 nm, respectively. Platelet After the ninth dose on day 5, blood samples were drawn aggregation was performed on the PACKS-4 platelet aggre- for the same assays immediately before undergoing leu- gometer (Helena Laboratories, Beaumont, TX, USA) using kapheresis. A personal diary was provided to all donors in 3 ␮mol/l ADP (Boehringer Mannheim, Indianapolis, IN, order to record prospectively any side-effects experienced USA). PT and aPTT were carried out on the Behring during the period of G-CSF administration. Side-effects Fibrintimer A (BFA, Behringwerke, Marburg, Germany) were graded by one investigator after discussion with the using Thromborel-S (Behring) and Automated APTT donor on a scale of 1 to 4; grade 1 were mild side-effects (Organon Teknika) respectively. FVIII:C was measured by with no intervention needed; grade 2 were moderate side- one stage clotting assay on the BFA instrument using effects needing some intervention (acetaminophen to immunoadsorbed FVIII deficient plasma (Dade, Miami, FL, relieve bone pain or fever) but not interfering with drug USA). vWF:Ag, ␤-TG, PF-4, TM and tPA:Ag were perfor- administration; grade 3 were severe side-effects interfering med by enzyme-linked immunosorbent assays (ELISA) with normal daily activity or with the need to discontinue using Asserachrom kits (Diagnostica Stago, Asnie`res-sur- medication; grade 4 were life-threatening complications Seine, France). vWF activity was determined using IMUB- related to the medication. In order to attribute symptoms IND vWF ELISA kit (American Diagnostica, Greenwich, only to G-CSF administration, all donors were instructed CT, USA). Enzygnost ELISA kits (Behringwerke) were to start recording symptoms in their diary 5 days prior to used for TAT and F1+2 determinations. ELISA assays were G-CSF administration. all carried out on CODA Automated EIA Analyzer (Bio- Rad, Hercules, CA, USA). Normal pooled plasma (NPP) Laboratory testing was used for calibration with a defined value of 1 U/ml.
Load more

Recommended publications
  • Recombinant Factors for Hemostasis
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Chemical & Biomolecular Engineering Theses, Chemical and Biomolecular Engineering, Dissertations, & Student Research Department of Summer 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra University of Nebraska at Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/chemengtheses Part of the Biochemical and Biomolecular Engineering Commons Calcaterra, Jennifer, "Recombinant Factors for Hemostasis" (2010). Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research. 5. https://digitalcommons.unl.edu/chemengtheses/5 This Article is brought to you for free and open access by the Chemical and Biomolecular Engineering, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Recombinant Factors for Hemostasis by Jennifer Calcaterra A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Interdepartmental Area of Engineering (Chemical & Biomolecular Engineering) Under the Supervision of Professor William H. Velander Lincoln, Nebraska August, 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra, Ph.D. University of Nebraska, 2010 Adviser: William H. Velander Trauma deaths are a result of hemorrhage in 37% of civilians and 47% military personnel and are the primary cause of death for individuals under 44 years of age. Current techniques used to treat hemorrhage are inadequate for severe bleeding. Preliminary research indicates that fibrin sealants (FS) alone or in combination with a dressing may be more effective; however, it has not been economically feasible for widespread use because of prohibitive costs related to procuring the proteins.
    [Show full text]
  • Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-Cov-2 Infection
    Journal of Autoimmunity 121 (2021) 102662 Contents lists available at ScienceDirect Journal of Autoimmunity journal homepage: www.elsevier.com/locate/jautimm Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection Dennis McGonagle a,b, Gabriele De Marco a, Charles Bridgewood a,* a Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK b National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK ARTICLE INFO ABSTRACT Keywords: Herein, we consider venous immunothrombotic mechanisms in SARS-CoV-2 infection and anti-SARS-CoV-2 DNA COVID-19 pneumonia related thrombosis vaccination. Primary SARS-CoV-2 infection with systemic viral RNA release (RNAaemia) contributes to innate Vaccine induced thrombotic thrombocytopenia immune coagulation cascade activation, with both pulmonary and systemic immunothrombosis - including (VITT) venous territory strokes. However, anti-SARS-CoV-2 adenoviral-vectored-DNA vaccines -initially shown for the Heparin induced thrombocytopenia (HIT) ChAdOx1 vaccine-may rarely exhibit autoimmunity with autoantibodies to Platelet Factor-4 (PF4) that is termed DNA-PF4 interactions. VITT model Vaccine-Induced Thrombotic Thrombocytopenia (VITT), an entity pathophysiologically similar to Heparin- Induced Thrombocytopenia (HIT). The PF4 autoantigen is a polyanion molecule capable of independent in­ teractions with negatively charged bacterial cellular wall, heparin and DNA molecules, thus linking intravascular innate immunity to both bacterial cell walls and pathogen-derived DNA. Crucially, negatively charged extra­ cellular DNA is a powerful adjuvant that can break tolerance to positively charged nuclear histone proteins in many experimental autoimmunity settings, including SLE and scleroderma. Analogous to DNA-histone inter­ actons, positively charged PF4-DNA complexes stimulate strong interferon responses via Toll-Like Receptor (TLR) 9 engagement.
    [Show full text]
  • Critical Role of CXCL4 in the Lung Pathogenesis of Influenza (H1N1) Respiratory Infection
    ARTICLES Critical role of CXCL4 in the lung pathogenesis of influenza (H1N1) respiratory infection L Guo1,3, K Feng1,3, YC Wang1,3, JJ Mei1,2, RT Ning1, HW Zheng1, JJ Wang1, GS Worthen2, X Wang1, J Song1,QHLi1 and LD Liu1 Annual epidemics and unexpected pandemics of influenza are threats to human health. Lung immune and inflammatory responses, such as those induced by respiratory infection influenza virus, determine the outcome of pulmonary pathogenesis. Platelet-derived chemokine (C-X-C motif) ligand 4 (CXCL4) has an immunoregulatory role in inflammatory diseases. Here we show that CXCL4 is associated with pulmonary influenza infection and has a critical role in protecting mice from fatal H1N1 virus respiratory infection. CXCL4 knockout resulted in diminished viral clearance from the lung and decreased lung inflammation during early infection but more severe lung pathology relative to wild-type mice during late infection. Additionally, CXCL4 deficiency decreased leukocyte accumulation in the infected lung with markedly decreased neutrophil infiltration into the lung during early infection and extensive leukocyte, especially lymphocyte accumulation at the late infection stage. Loss of CXCL4 did not affect the activation of adaptive immune T and B lymphocytes during the late stage of lung infection. Further study revealed that CXCL4 deficiency inhibited neutrophil recruitment to the infected mouse lung. Thus the above results identify CXCL4 as a vital immunoregulatory chemokine essential for protecting mice against influenza A virus infection, especially as it affects the development of lung injury and neutrophil mobilization to the inflamed lung. INTRODUCTION necrosis factor (TNF)-a, interleukin (IL)-6, and IL-1b, to exert Influenza A virus (IAV) infections cause respiratory diseases in further antiviral innate immune effects.2 Meanwhile, the innate large populations worldwide every year and result in seasonal immune cells act as antigen-presenting cells and release influenza epidemics and unexpected pandemic.
    [Show full text]
  • Inflammatory Modulation of Hematopoietic Stem Cells by Magnetic Resonance Imaging
    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2014 Inflammatory modulation of hematopoietic stem cells by Magnetic Resonance Imaging (MRI)-detectable nanoparticles Sezin Aday1,2*, Jose Paiva1,2*, Susana Sousa2, Renata S.M. Gomes3, Susana Pedreiro4, Po-Wah So5, Carolyn Ann Carr6, Lowri Cochlin7, Ana Catarina Gomes2, Artur Paiva4, Lino Ferreira1,2 1CNC-Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal, 2Biocant, Biotechnology Innovation Center, Cantanhede, Portugal, 3King’s BHF Centre of Excellence, Cardiovascular Proteomics, King’s College London, London, UK, 4Centro de Histocompatibilidade do Centro, Coimbra, Portugal, 5Department of Neuroimaging, Institute of Psychiatry, King's College London, London, UK, 6Cardiac Metabolism Research Group, Department of Physiology, Anatomy & Genetics, University of Oxford, UK, 7PulseTeq Limited, Chobham, Surrey, UK. *These authors contributed equally to this work. #Correspondence to Lino Ferreira ([email protected]). Experimental Section Preparation and characterization of NP210-PFCE. PLGA (Resomers 502 H; 50:50 lactic acid: glycolic acid) (Boehringer Ingelheim) was covalently conjugated to fluoresceinamine (Sigma- Aldrich) according to a protocol reported elsewhere1. NPs were prepared by dissolving PLGA (100 mg) in a solution of propylene carbonate (5 mL, Sigma). PLGA solution was mixed with perfluoro- 15-crown-5-ether (PFCE) (178 mg) (Fluorochem, UK) dissolved in trifluoroethanol (1 mL, Sigma). This solution was then added to a PVA solution (10 mL, 1% w/v in water) dropwise and stirred for 3 h. The NPs were then transferred to a dialysis membrane and dialysed (MWCO of 50 kDa, Spectrum Labs) against distilled water before freeze-drying. Then, NPs were coated with protamine sulfate (PS).
    [Show full text]
  • Hematopoiesis and Hemostasis
    Hematopoiesis and Hemostasis HAP Susan Chabot Hematopoiesis • Blood Cell Formation • Occurs in red bone marrow – Red marrow - found in flat bones and proximal epiphyses of long bones. • Each type of blood cell is produced in response to changing needs of the body. • On average, an ounce of new blood is produced each day with about 100 billion new blood cells/formed elements. Hemocytoblast • Hemo- means blood • Cyto- means cell • -blast means builder • Blood stem cell found in red bone marrow. • Once the precursor cell has committed to become a specific blood type, it cannot be changed. Hemocytoblast Erythropoiesis • Erythrocyte Formation • Because they are anucleated, RBC’s must be regularly replaced. – No info to synthesize proteins, grow or divide. • They begin to fall apart in 100 - 120 days. • Remains of fragmented RBC’s are removed by the spleen and liver. • Entire development , release, and ejection of leftover organelles takes 3-5 days. Normal RBC’s Reticulocytes • The stimulus for RBC production is the amount of OXYGEN in the blood not the NUMBER of RBC’s. • The rate of RBC production is controlled by the hormone ERYTHROPOIETIN. Leuko- and Thrombopoiesis • Leukopoesis = WBC production • Thrombopoesis = platelet production • Controlled by hormones Leukopoesis Thrombopoesis • (CSF) Colony • Thrombopoetin stimulating factor • Little is known • Interleukins about this – Prompts WBC process. production – Boosts other immune processes including inflammation. HEMOSTASIS Hemostasis • Hemo- means blood • -stasis means standing still – Stoppage of bleeding • Fast and localized reaction when a blood vessel breaks. • Involves a series of reactions. • Involves substances normally found in plasma but not activated. • Occurs in 3 main phases Phases of Hemostasis • Step 1: Vascular Spasm – Vasoconstriction, narrowing of blood vessels.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Notch and TLR Signaling Coordinate Monocyte Cell Fate and Inflammation
    RESEARCH ARTICLE Notch and TLR signaling coordinate monocyte cell fate and inflammation Jaba Gamrekelashvili1,2*, Tamar Kapanadze1,2, Stefan Sablotny1,2, Corina Ratiu3, Khaled Dastagir1,4, Matthias Lochner5,6, Susanne Karbach7,8,9, Philip Wenzel7,8,9, Andre Sitnow1,2, Susanne Fleig1,2, Tim Sparwasser10, Ulrich Kalinke11,12, Bernhard Holzmann13, Hermann Haller1, Florian P Limbourg1,2* 1Vascular Medicine Research, Hannover Medical School, Hannover, Germany; 2Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; 3Institut fu¨ r Kardiovaskula¨ re Physiologie, Fachbereich Medizin der Goethe-Universita¨ t Frankfurt am Main, Frankfurt am Main, Germany; 4Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany; 5Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; 6Mucosal Infection Immunology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany; 7Center for Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; 8Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; 9German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Mainz, Germany; 10Department of Medical Microbiology and Hygiene, Medical Center of the Johannes Gutenberg- University of Mainz, Mainz, Germany; 11Institute for Experimental Infection Research, TWINCORE, Centre for
    [Show full text]
  • Human Alveolar Macrophages Synthesize Factor VII in Vitro
    Human alveolar macrophages synthesize factor VII in vitro. Possible role in interstitial lung disease. H A Chapman Jr, … , O L Stone, D S Fair J Clin Invest. 1985;75(6):2030-2037. https://doi.org/10.1172/JCI111922. Research Article Both fibrin and tissue macrophages are prominent in the histopathology of chronic inflammatory pulmonary disease. We therefore examined the procoagulant activity of freshly lavaged human alveolar macrophages in vitro. Intact macrophages (5 X 10(5) cells) from 13 healthy volunteers promoted clotting of whole plasma in a mean of 65 s. Macrophage procoagulant activity was at least partially independent of exogenous Factor VII as judged by a mean clotting time of 99 s in Factor VII-deficient plasma and by neutralization of procoagulant activity by an antibody to Factor VII. Immunoprecipitation of extracts of macrophages metabolically labeled with [35S]methionine by Factor VII antibody and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a labeled protein consistent in size with the known molecular weight of blood Factor VII, 48,000. The addition of 50 micrograms of unlabeled, purified Factor VII blocked recovery of the 48,000-mol wt protein. In addition, supernatants of cultured macrophages from six normal volunteers had Factor X-activating activity that was suppressed an average of 71% after culture in the presence of 50 microM coumadin or entirely by the Factor VII antibody indicating that Factor VII synthesized by the cell was biologically active. Endotoxin in vitro induced increases in cellular tissue factor but had no consistent effect on macrophage Factor VII activity. We also examined the tissue factor and Factor VII activities […] Find the latest version: https://jci.me/111922/pdf Human Alveolar Macrophages Synthesize Factor VII In Vitro Possible Role in Interstitial Lung Disease Harold A.
    [Show full text]
  • Ferric Sulfate Hemostasis: Effect on Osseous Wound Healing, II, with Curettage and Irrigation
    0099-2399/93/1904-0174/$03.00/0 JOURNAL OF ENDODONTICS Printed in U.S.A. Copyright © 1993 by The American Association of Endodontists VOL. 19, No. 4, APRIL 1993 Ferric Sulfate Hemostasis: Effect on Osseous Wound Healing, II, With Curettage and Irrigation Billie G. Jeansonne, DDS, PhD, William S. Boggs, DDS, MS, and Ronald R. Lemon, DMD Hemorrhage control is often a problem for the clini- MATERIALS AND METHODS cian during osseous surgery. Ferric sulfate is an effective hemostatic agent, but with prolonged ap- The experiments were performed in 12 New Zealand White plication to an osseous defect can cause persistent rabbits (2.3 to 3.7 kg). Anesthesia was obtained by the intra- inflammation and delayed healing. The purpose of muscular injection of a combination of xylazine (7 mg/kg), ketamine (30 mg/kg), and atropine (0.3 mg/kg). On both this investigation was to evaluate the effectiveness sides of the mandible, an incision was made along the alveolar of ferric sulfate as a hemostatic agent and to deter- crest in the naturally edentulous space between the incisor mine its effect on healing after thorough curettage and premolar teeth. An envelope flap was reflected to expose and irrigation from osseous surgical wounds. Stand- the alveolar cortical bone. An osseous defect (3 mm in di- ard size osseous defects were created bilaterally in ameter, 2 mm into cancellous bone) was created on each side the mandibles of rabbits. Ferric sulfate was placed with a #8 round bur. All defects were curetted and irrigated in one defect until hemostasis was obtained; the with saline.
    [Show full text]
  • Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
    cells Review Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead Tahereh Soltantoyeh 1,†, Behnia Akbari 1,† , Amirali Karimi 2, Ghanbar Mahmoodi Chalbatani 1 , Navid Ghahri-Saremi 1, Jamshid Hadjati 1, Michael R. Hamblin 3,4 and Hamid Reza Mirzaei 1,* 1 Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran; [email protected] (T.S.); [email protected] (B.A.); [email protected] (G.M.C.); [email protected] (N.G.-S.); [email protected] (J.H.) 2 School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran; [email protected] 3 Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa; [email protected] 4 Radiation Biology Research Center, Iran University of Medical Sciences, Tehran 1449614535, Iran * Correspondence: [email protected]; Tel.: +98-21-64053268; Fax: +98-21-66419536 † Equally contributed as first author. Abstract: Metastatic melanoma is the most aggressive and difficult to treat type of skin cancer, with a survival rate of less than 10%. Metastatic melanoma has conventionally been considered very difficult to treat; however, recent progress in understanding the cellular and molecular mechanisms involved in the tumorigenesis, metastasis and immune escape have led to the introduction of new therapies. Citation: Soltantoyeh, T.; Akbari, B.; These include targeted molecular therapy and novel immune-based approaches such as immune Karimi, A.; Mahmoodi Chalbatani, G.; checkpoint blockade (ICB), tumor-infiltrating lymphocytes (TILs), and genetically engineered T- Ghahri-Saremi, N.; Hadjati, J.; lymphocytes such as chimeric antigen receptor (CAR) T cells.
    [Show full text]
  • Chemokines and Their Receptors in Rheumatoid Arthritis
    ARTHRITIS & RHEUMATISM Vol. 52, No. 3, March 2005, pp 710–721 DOI 10.1002/art.20932 © 2005, American College of Rheumatology REVIEW Chemokines and Their Receptors in Rheumatoid Arthritis Future Targets? Alisa E. Koch Introduction tem was introduced in 2000, in which chemokines are considered as chemokine ligands, and each chemokine Rheumatoid arthritis (RA) is a chronic inflam- has been assigned a designation of CXCL, CCL, XCL, matory disease leading to joint destruction (1). In RA, or CX3CL1 (Figure 1) (10–12). In this report, both the migration of leukocytes into the synovial tissue (ST) former and new nomenclature are noted. occurs. These leukocytes and other cells in the ST, particularly RA ST fibroblasts, produce mediators of CXC chemokines have 2 conserved cysteines inflammation, including chemokines (1). Chemokines, separated by 1 unconserved amino acid (9,13) (Figure currently numbering more than 50, are chemotactic 1). CXC chemokines classically were thought to be cytokines that are important in recruitment of leuko- involved in the chemotaxis of neutrophils. Many chemo- cytes and angiogenesis. They exert chemotactic activity kines may have arisen from reduplication of ancestral toward a variety of cell types (2–7). Some chemokines, genes (13). Hence, CXC chemokines that act on neutro- particularly CXC chemokines containing the ELR motif, phils are clustered on chromosome 4q12–13 (13). How- are angiogenic. The last few years have seen a rapid ever, some genes of more newly discovered CXC che- development of studies aimed at targeting proinflamma- mokines that recruit lymphocytes tend to be located tory chemokines or their receptors in RA and animal away from the major clusters (13).
    [Show full text]
  • Pulmonary Megakaryocytes in Coronavirus Disease 2019 (COVID-19): Roles in Thrombi and Fibrosis
    Published online: 2020-09-03 Commentary 831 Pulmonary Megakaryocytes in Coronavirus Disease 2019 (COVID-19): Roles in Thrombi and Fibrosis Jecko Thachil, MD, FRCP1 Ton Lisman, PhD2 1 Department of Haematology, Manchester Royal Infirmary, Address for correspondence Jecko Thachil, MD, FRCP, Department of Manchester, United Kingdom Haematology, Manchester Royal Infirmary, Oxford Road, Manchester 2 Surgical Research Laboratory and Section of Hepatobiliary Surgery M13 9WL, United Kingdom (e-mail: [email protected]). and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Semin Thromb Hemost 2020;46:831–834. Coronavirus disease 2019 (COVID-19) has already claimed karyocyte presence in the lungs assert that lung megakaryo- many lives and continues to do so in different parts of the cytes just represent a gravity phenomenon noted at autopsy. world. Autopsy reports of patients who succumbed to this viral The mostelegant (and latest)study for validating thelungorigin infection have been published despite concerns about health of platelets comes from Lefrançais et al who directly imaged the care professional safety. One of the unusual findings in COVID- lung microcirculation in mice to provide definite proof for the 19 lung autopsy reports is the increase in pulmonary mega- existence of lung megakaryocytes.8 They also proved that karyocytes.1,2 Although the presence of megakaryocytes in the approximately halfof the total number of platelets or 10 million lungs is a well-established concept in the medical literature, it platelets per hour would be produced by these cells.8 is still not widely accepted in the clinical fraternity.
    [Show full text]